Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 15/20 | 0.63 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30446566 | 0.99 | MAP4K1 (0.62) | MAP4K1AXLALKEGFR | |
| SCHEMBL30184078 | 0.92 | MAP4K1 (0.62) | MAP4K1AXLALKEGFR | |
| Hydrochloric Acid SCHEMBL30184357 | 0.91 | MAP4K1 (0.61) | MAP4K1AXLALKEGFR | |
| SCHEMBL30183977 | 0.90 | MAP4K1 (0.77) | MAP4K1ALK | |
| SCHEMBL25947737 | 0.89 | MAP4K1 (0.61) | MAP4K1ALK | |
| SCHEMBL20214480 | 0.87 | MAP4K1 (0.81) | MAP4K1ALKEGFR | |
| SCHEMBL30446890 | 0.85 | MAP4K1 (0.58) | MAP4K1ALKEGFR | |
| SCHEMBL25338017 | 0.84 | MAP4K1 (0.65) | MAP4K1ALKEGFR | |
| SCHEMBL30184160 | 0.83 | MAP4K1 (0.77) | MAP4K1ALK | |
| SCHEMBL25337664 | 0.83 | MAP4K1 (0.77) | MAP4K1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | claimed |
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | claimed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | claimed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | MAP4K1 23/4885AXL 146/4885ALK 150/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | MAP4K1 1/4885AXL 2986/4885ALK 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.